---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009950"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:48:01.486600+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics FY2023 revenue drops 80% to $6.8M; net loss widens to $35.3M

## Summary
- Revenue of $6.8M, down from $34.2M in 2022, driven by decline in COVID-19 test demand.
- Net loss of $35.3M ($1.20 per diluted share) vs. $14.2M ($0.45) in prior year.
- Operating loss of $42.7M; adjusted EBITDA loss of $33.0M.
- Submitted EUA to FDA for Co-Dx PCR Pro platform and COVID-19 test in December 2023.
- Appointed Ivory Chang as Chief Regulatory Affairs Officer; secured $12.6M in grants for TB, respiratory, HPV tests.

## SEC filing metadata
- accession: 0001493152-24-009950
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009950
- JSON: https://secwatch.observer/filing/0001493152-24-009950.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009950.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported the full year ended December 31, 2023 results: revenue $6.8 million, net income Net loss of $35.3 million, EPS a loss of $1.20 per fully diluted share.
  - Period: the full year ended December 31, 2023
  - Revenue: $6.8 million
  - Net income: Net loss of $35.3 million
  - EPS: a loss of $1.20 per fully diluted share
  - Result: reported results
  source text: the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: ● Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests. Grant revenue totaled $5.8 million while
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315224009950/0001493152-24-009950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.